Academic Journal
Delayed Treatment of Ischemia/Reperfusion Brain Injury ; Extended Therapeutic Window with the Proteosome Inhibitor MLN519
| العنوان: | Delayed Treatment of Ischemia/Reperfusion Brain Injury ; Extended Therapeutic Window with the Proteosome Inhibitor MLN519 |
|---|---|
| المؤلفون: | Williams, Anthony J., Berti, Rossana, Dave, Jitendra R., Elliot, Peter J., Adams, Julian, Tortella, Frank C. |
| المصدر: | Stroke ; volume 35, issue 5, page 1186-1191 ; ISSN 0039-2499 1524-4628 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health) |
| سنة النشر: | 2004 |
| الوصف: | Background and Purpose— Clinical development of novel neuroprotection therapies for the treatment of brain injury has been unsuccessful. One critical limitation is the lack of a viable therapeutic treatment window (TW). In this study, we evaluated the neuroprotection TW for the proteosome inhibitor MLN519 after ischemia/reperfusion brain injury in rats as related to its antiinflammatory mechanism. Methods— Male Sprague-Dawley rats were subjected to 2 hours of middle cerebral artery occlusion (MCAo), followed by 70 hours of reperfusion and recovery. MLN519 was administered after injury (starting 6 to 12 hours after MCAo) to evaluate the full TW. Brain infarction, neuronal degeneration, neurological recovery, leukocyte infiltration, and inflammatory gene mRNA levels were assessed. Results— Core infarct volume in vehicle-treated rats (216±25 mm 3 ) was reduced with delayed MLN519 treatments of 6, 8, or 10 hours after injury (45±13, 86±28, and 150±27 mm 3 , respectively, P <0.05) and was associated with reductions in neuronal and axonal degeneration. MLN519-treated rats had reduced brain mRNA levels of TNF-α (46%, P <0.05), ICAM-1 (58%, P <0.05), IL-6 (58%, P <0.05), and E-selectin (72%, P <0.05) at 24 hours after injury. Furthermore, MLN519 treatment reduced leukocyte infiltration by 32% to 80% ( P <0.05) in ischemic brain regions. Conclusions— Neuroprotection treatment with MLN519 provides an extended TW of up to 10 hours after ischemia/reperfusion brain injury, in part by attenuating the inflammatory response. As such, the delayed onset of brain inflammation after an ischemic injury offers a prime target for extending the neuroprotective TW with compounds such as MLN519, used either alone or possibly as an adjunctive therapy with thrombolytic agents. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1161/01.str.0000125721.10606.dc |
| DOI: | 10.1161/01.STR.0000125721.10606.dc |
| الاتاحة: | http://dx.doi.org/10.1161/01.str.0000125721.10606.dc https://www.ahajournals.org/doi/full/10.1161/01.STR.0000125721.10606.dc |
| رقم الانضمام: | edsbas.FDA18DFE |
| قاعدة البيانات: | BASE |
| DOI: | 10.1161/01.str.0000125721.10606.dc |
|---|